HUE053939T2 - Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk - Google Patents

Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk

Info

Publication number
HUE053939T2
HUE053939T2 HUE15725253A HUE15725253A HUE053939T2 HU E053939 T2 HUE053939 T2 HU E053939T2 HU E15725253 A HUE15725253 A HU E15725253A HU E15725253 A HUE15725253 A HU E15725253A HU E053939 T2 HUE053939 T2 HU E053939T2
Authority
HU
Hungary
Prior art keywords
heterocyclic compounds
contrast agents
imaging contrast
deuterated
deuterated heterocyclic
Prior art date
Application number
HUE15725253A
Other languages
English (en)
Hungarian (hu)
Inventor
Jan Marik
Joseph P Lyssikatos
Simon Williams
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HUE053939T2 publication Critical patent/HUE053939T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HUE15725253A 2014-05-13 2015-05-12 Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk HUE053939T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461992717P 2014-05-13 2014-05-13

Publications (1)

Publication Number Publication Date
HUE053939T2 true HUE053939T2 (hu) 2021-08-30

Family

ID=53269446

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15725253A HUE053939T2 (hu) 2014-05-13 2015-05-12 Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk

Country Status (21)

Country Link
US (4) US10076581B2 (enExample)
EP (2) EP3901145A1 (enExample)
JP (2) JP6529986B2 (enExample)
KR (2) KR102530129B1 (enExample)
CN (2) CN110483522B (enExample)
AU (2) AU2015261008B2 (enExample)
CA (1) CA2948721C (enExample)
DK (1) DK3143011T3 (enExample)
ES (1) ES2867814T3 (enExample)
HR (1) HRP20210641T1 (enExample)
HU (1) HUE053939T2 (enExample)
IL (3) IL280791B2 (enExample)
LT (1) LT3143011T (enExample)
MX (2) MX384604B (enExample)
PL (1) PL3143011T3 (enExample)
PT (1) PT3143011T (enExample)
RS (1) RS61810B1 (enExample)
RU (1) RU2696492C2 (enExample)
SG (2) SG10201805628TA (enExample)
SI (1) SI3143011T1 (enExample)
WO (1) WO2015173225A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948721C (en) * 2014-05-13 2023-03-28 F. Hoffmann-La Roche Ag Deuterated compounds and uses thereof
JP7197476B2 (ja) 2016-07-22 2022-12-27 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
JP7286539B2 (ja) * 2016-11-01 2023-06-05 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化protac、および関連使用方法
CA3072362A1 (en) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibiting ubiquitin specific peptidase 30
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
US11306089B2 (en) 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
US11623927B2 (en) 2018-03-02 2023-04-11 The Trustees Of The University Of Pennsylvania Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
RS65335B1 (sr) 2018-10-05 2024-04-30 Annapurna Bio Inc Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću receptora apj
MY209034A (en) 2018-10-05 2025-06-17 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7119978B2 (ja) * 2018-12-20 2022-08-17 オムロン株式会社 制御装置およびプログラム
CN114423763B (zh) * 2019-05-09 2025-01-21 豪夫迈·罗氏有限公司 咪唑并[1,2-a]嘧啶的区域选择性合成
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
CN113526526A (zh) * 2021-07-12 2021-10-22 苏州大学 氘代氨制备方法及以其作为氘源参与的氘代反应
CA3228359A1 (en) 2021-08-27 2023-03-02 Genentech, Inc. Methods of treating tau pathologies
EP4536358A1 (en) 2022-06-13 2025-04-16 Genentech Inc. Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
WO2025155625A1 (en) * 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging
CN118957609B (zh) * 2024-07-23 2025-09-09 无锡绿能电合科技有限公司 一种氟代芳环的氘代方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE76515C (de) F. MORA in Mailand Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff
DD76515A (enExample) *
EP1340759A1 (en) * 2002-02-28 2003-09-03 Sanofi-Synthelabo 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives
US6875784B2 (en) 2002-10-09 2005-04-05 Pharmacia & Upjohn Company Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives
HUE032660T2 (en) * 2006-03-30 2017-10-30 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
SI2247558T2 (sl) 2008-02-14 2024-10-30 Eli Lilly And Company Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100144657A1 (en) 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8491869B2 (en) 2009-03-23 2013-07-23 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2450332A1 (en) 2010-10-22 2012-05-09 Bayer Pharma Aktiengesellschaft Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
NZ610315A (en) * 2010-11-15 2015-08-28 Univ Leuven Kath Antiviral condensed heterocyclic compounds
WO2013176698A1 (en) * 2012-05-22 2013-11-28 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
CN105358558B (zh) * 2013-10-08 2017-09-26 豪夫迈·罗氏有限公司 作为tau‑pet‑配体的二氮杂咔唑衍生物
CA2948721C (en) 2014-05-13 2023-03-28 F. Hoffmann-La Roche Ag Deuterated compounds and uses thereof

Also Published As

Publication number Publication date
AU2019203369B2 (en) 2020-06-04
IL271631B (en) 2021-05-31
JP6681498B2 (ja) 2020-04-15
NZ764181A (en) 2023-11-24
US20230218782A1 (en) 2023-07-13
JP2019147825A (ja) 2019-09-05
US10675367B2 (en) 2020-06-09
CN110483522B (zh) 2022-05-03
PT3143011T (pt) 2021-04-26
AU2015261008B2 (en) 2019-02-14
MX2016014615A (es) 2017-03-06
US11504440B2 (en) 2022-11-22
RS61810B1 (sr) 2021-06-30
US20160250358A1 (en) 2016-09-01
DK3143011T3 (da) 2021-05-03
ES2867814T3 (es) 2021-10-20
LT3143011T (lt) 2021-05-10
US20200297875A1 (en) 2020-09-24
MX384604B (es) 2025-03-14
KR20230035445A (ko) 2023-03-13
IL280791B2 (en) 2024-03-01
WO2015173225A1 (en) 2015-11-19
US12214058B2 (en) 2025-02-04
KR20170002639A (ko) 2017-01-06
RU2016147742A3 (enExample) 2018-10-08
JP6529986B2 (ja) 2019-06-12
US20190201561A1 (en) 2019-07-04
NZ726208A (en) 2023-11-24
CN110483522A (zh) 2019-11-22
BR112016026443A2 (pt) 2017-08-15
IL248692A0 (en) 2017-01-31
EP3901145A1 (en) 2021-10-27
PL3143011T3 (pl) 2021-07-19
CN106459059B (zh) 2019-09-24
MX376163B (es) 2025-03-07
SG11201609281UA (en) 2016-12-29
RU2696492C2 (ru) 2019-08-02
SG10201805628TA (en) 2018-08-30
CA2948721C (en) 2023-03-28
CN106459059A (zh) 2017-02-22
EP3143011A1 (en) 2017-03-22
EP3143011B1 (en) 2021-03-03
BR112016026443A8 (pt) 2021-07-06
IL280791A (en) 2021-04-29
KR102618139B1 (ko) 2023-12-27
IL271631A (en) 2020-02-27
AU2015261008A1 (en) 2016-11-17
IL280791B1 (en) 2023-11-01
SI3143011T1 (sl) 2021-08-31
US10076581B2 (en) 2018-09-18
AU2019203369A1 (en) 2019-06-06
IL248692B (en) 2020-01-30
MX2020010847A (es) 2021-07-16
CA2948721A1 (en) 2015-11-19
RU2016147742A (ru) 2018-06-18
HRP20210641T1 (hr) 2021-05-28
JP2017515856A (ja) 2017-06-15
KR102530129B1 (ko) 2023-05-10

Similar Documents

Publication Publication Date Title
HUE053939T2 (hu) Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
IL285760A (en) Deuterated or a non-deuterated molecule and pharmaceutical formulations
HUE055755T2 (hu) Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk
EP3417768C0 (en) IMAGING PROCESS
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
HUE046000T2 (hu) Antiproferatív vegyületek és alkalmazásuk módszerei
HUE052771T2 (hu) C10orf54 elleni antitestek és alkalmazásuk
CL2016002364A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparación y uso de las mismas
HUE057734T2 (hu) Heterociklusos vegyületek és alkalmazásuk
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
BR112016030368A2 (pt) composição oftálmica
HUE055473T2 (hu) Difluormetil-aminopiridinek és difluormetil-aminopirimidinek
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
HUE051713T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és ezek alkalmazása
EP3528737A4 (en) MEDICAL SUPPORT
HUE054245T2 (hu) Immunszupresszáns formuláció
HUE060805T2 (hu) Piridinamin-piridon és pirimidinamin-piridon vegyületek
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
LT3231793T (lt) Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas
IL264445A (en) Compounds and compositions and uses thereof
FR3027119B1 (fr) Dispositif d'imagerie duale
DK3190964T3 (da) Spirometer
HUE050565T2 (hu) Pirazolotiazol vegyület és azt tartalmazó gyógyszer
ITUB20156000A1 (it) Composizione nematocida e suo utilizzo
DK3148513T3 (da) Ceritinib-formulering